Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Inovirus M13 strain:SP063

ABSTRACT: Development of potent in vivo mutagenesis plasmids with broad mutational spectra

PROVIDER: PRJNA294841 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR2262700.fastq.gz	Fastqsanger.gz
	SRR2262710.fastq.gz	Fastqsanger.gz
	SRR2262720.fastq.gz	Fastqsanger.gz
	SRR2262701.fastq.gz	Fastqsanger.gz
	SRR2262711.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 30

Similar Datasets

Inovirus M13

Project description:M13 bacteriophage random peptide phage display libraries selected for binding to serum antibodies

| PRJNA196935 | ENA

Inovirus M13

Project description:Inovirus M13 Targeted Locus (Loci)

| PRJNA270317 | ENA

Inovirus M13

Project description:Inovirus M13 Raw sequence reads

| PRJNA397152 | ENA

Inovirus M13

Project description:Bacteriophage M13 Raw sequence reads

| PRJNA356430 | ENA

Inovirus M13

Project description:Profiling active site specificity for proteases ADAMTS13 and Thrombin

| PRJNA356764 | ENA

Inovirus M13

Project description:Inovirus M13 Raw sequence reads

| PRJNA316731 | ENA

Inovirus M13 strain:NEB PhD-12 kit

Project description:High-throughput phage display screening of S100 protein family

| PRJNA646756 | ENA

Exome Sequencing of Esophageal Adenocarcinoma

Project description:<p>The incidence of esophageal adenocarcinoma (EAC) has risen 600% over the last 30 years. When coupled to the five-year survival rate of only 15% for this disease, identification of new therapeutic targets for EAC is of great importance. Here, we analyze the mutational spectra identified from the whole genome sequencing of 16 EACs and complete exome sequencing of 149 EAC tumors and matched germline samples. We identify a novel mutation signature marked by high prevalence of A to C transversions at AA*(N) trinucleotides. Notably, the development of EAC is preceded by pathologic intestinal metaplasia of the lower esophagus, Barrett's esophagus, itself a response to injury from gastric-esophageal reflux disease (GERD). Thus, we hypothesize to represent these AA*(N) mutations to a novel signature of GERD-induced mutagenesis. Analysis of the exome data identified 26 genes subject to statistically significant recurrent mutation. Of these 26 genes, only TP53, CDKN2A, SMAD4, and PIK3CA had been previously implicated in EAC. Novel mutations include those targeting chromatin modifying factors and novel candidate contributors to EAC: SPG20, TLR4, ELMO1 and DOCK2. Of these, ELMO1 and DOCK2 are notably direct dimerization partners that act to activate Rac1 to enhance cellular invasiveness, thus generating new hypotheses about the potential for the Rac1 pathway to be a novel target for therapy of EAC.</p> <p>"Reprinted from 'Unraveling the mutational complexity of esophageal adenocarcinoma', with permission from Nature Genetics."</p>

| phs000598 | dbGaP

TET2 lesions enhance the aggressiveness of CEBPA-mutant AML by re-balancing GATA2 expression

Project description:The myeloid transcription factor CEBPA is recurrently biallelically mutated (i.e., double mutated; CEBPADM) in acute myeloid leukemia (AML); with a combination of hypermorphic N-terminal mutations (CEBPANT), promoting expression of the leukemia-associated p30 isoform, and amorphic C-terminal mutations. CEBPADM AML features recurrent co‑occurring mutations; however, insight into the underlying mechanisms for the co-mutational spectra is incomplete. By combining transcriptomic and epigenomic analyses of data from CEBPA-TET2-co-mutant patients with experimental models thereof, we identify GATA2 as a conserved target of the CEBPA-TET2 mutational axis, providing a rationale for the mutational spectra in CEBPADM AML. Mechanistically, we suggest that elevated CEBPA levels, driven by the CEBPANT, mediate recruitment of TET2 to the GATA2 distal hematopoietic enhancer and thereby increase GATA2 expression. Conversely, CEBPADM AML gains a competitive advantage by loss of TET2; decreasing GATA2 promoter demethylation and re-balancing GATA2 levels. Further, demethylating treatment of CEBPA-TET2-co-mutant AML restores GATA2 levels, and prolongs disease latency.

2023-08-28 | GSE214224 | GEO

Mus musculus strain:C57BL/6

Project description:Mutational spectra produced by N-nitrosodimethylamine and SN1 chemotherapeutic agents

| PRJNA910200 | ENA